Article
Oncology
Xiangqian Zheng, Zhengang Xu, Qinghai Ji, Minghua Ge, Feng Shi, Jianwu Qin, Feng Wang, Guang Chen, Yuan Zhang, Rui Huang, Jian Tan, Tao Huang, Sijin Li, Zhongwei Lv, Yansong Lin, Zhuming Guo, Tomoki Kubota, Takuya Suzuki, Hiroki Ikezawa, Ming Gao
Summary: In Chinese patients with radioiodine-refractory differentiated thyroid cancer, treatment with lenvatinib at a starting dose of 24 mg/day significantly improved progression-free survival and objective response rate compared to placebo, with no new or unexpected toxicities observed. These results are consistent with those from the multinational phase III SELECT study involving patients with RR-DTC.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Susana M. Campos, Suzanne Berlin, Carolyn N. Krasner, Christin Whalen, Tina Atkinson, Kristin Meegan, Lauren Pereira, Karin Tyburski, Weixiu Lou, Hang Lee, Neil Horowitz, Richard T. Penson
Summary: The study aimed to investigate the safety of Temsirolimus and AZD2171 in patients with gynecological malignancies, and to evaluate the maximum tolerated dose of the combination. However, the study was halted at dose level 1 due to significant toxicities, and no maximum tolerated dose was determined.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Siqing Fu, David E. Piccioni, Hongtao Liu, Rimas Lukas, Santosh Kesari, Dawit Aregawi, David S. Hong, Kenichiro Yamaguchi, Kate Whicher, Yi Zhang, Yu-Luan Chen, Nagaraju Poola, John Eddy, David Blum
Summary: WT2725 is a WT1-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1(+) tumors in patients with HLA-A*0201(+) and/or HLA-A*0206(+). The phase I study showed that WT2725 dosing emulsion was well tolerated, with promising antitumor activity in malignancies known to overexpress the WT1 protein, especially in glioblastoma patients.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Kiyohiko Hatake, Takaaki Chou, Toshihiko Doi, Yasuhito Terui, Harumi Kato, Takayuki Hirose, Sachiko Seo, Michael Pourdehnad, Yumi Ogaki, Hiroshi Fujimoto, Patrick R. Hagner, Kazuhito Yamamoto
Summary: Avadomide, a novel cereblon-binding agent, showed acceptable toxicity profile and clinically meaningful efficacy in Japanese patients with advanced solid tumors or NHL, with an overall response rate of 54%.
Article
Oncology
Yukata Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, Christine Lihou, Tao Ji, Chenwei Tian, Toshio Shimizu
Summary: This study reported the safety, tolerability, and preliminary efficacy of pemigatinib in Japanese patients with advanced solid tumors. The results showed that pemigatinib demonstrated manageable adverse events, consistent pharmacokinetics and pharmacodynamics profiles, and preliminary efficacy in these patients.
Article
Oncology
Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice Chen, Jan H. Beumer, Janice M. Mehnert
Summary: The study aimed to evaluate the safety and efficacy of Veliparib in combination with cyclophosphamide and doxorubicin, showing that these combinations are safe and active in patients with metastatic breast cancer.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
Deborah M. Stephens, Ying Huang, Amy S. Ruppert, Janek S. Walker, Casey B. Cempre, Qiang Fu, Sharyn Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry A. Rogers, Seema Bhat, Samantha M. Jaglowski, Hank Lockman, Rosa Lapalombella, John C. Byrd, Jennifer A. Woyach
Summary: The combination of selinexor and ibrutinib has demonstrated tolerability and durable responses in patients with relapsed/refractory CLL/NHL. Notable responses were seen in patients with CLL with minimal prior therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sarina A. Piha-Paul, Kyaw Z. Thein, Paul De Souza, Richard Kefford, Tara Gangadhar, Christopher Smith, Shelly Schuster, William C. Zamboni, Claire E. Dees, Ben Markman
Summary: This study investigated the tolerability, efficacy, and pharmacokinetics/pharmacodynamics of CRLX301, a nanoparticle formulation of docetaxel. Results showed acceptable safety profile and preliminary evidence of tumor efficacy in heavily pretreated patients, with further research needed to determine optimal dose and schedule.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Biochemistry & Molecular Biology
Yi Que, Juan Wang, Feifei Sun, Shan Wang, Jia Zhu, Junting Huang, Zhenzhen Zhao, Li Zhang, Juan Liu, Jiaqian Xu, Zijun Zhen, Xiaofei Sun, Suying Lu, Yizhuo Zhang
Summary: The aim of this study was to evaluate the safety and efficacy of sintilimab in pediatric patients with advanced or recurrent malignancies for the first time. The results showed that sintilimab had good tolerability and promising anti-tumor effects in pediatric Hodgkin lymphoma.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Wen Wee Ma, Jenny J. Li, Nilofer S. Azad, Elaine T. Lam, Jennifer R. Diamond, Grace K. Dy, Mateusz Opyrchal, Jay Zhi, Douglas Kramer, Wing-Kai Chan, David Cutler, Rudolf Kwan, Alex A. Adjei, Antonio Jimeno
Summary: The purpose of this study was to determine the maximum-tolerated dose of Oraxol, an oral formulation of paclitaxel, in patients with advanced malignancies. The study found that the recommended phase II dose of Oraxol was 270 mg daily x 5 days per week. Adverse events were primarily fatigue, neutropenia, and nausea/vomiting. Pharmacokinetic analysis showed rapid absorption of paclitaxel when administered orally.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Tomoko Fujita, Ko Sugibayashi, Kosho Murayama, Noboru Yamamoto
Summary: This study evaluated the safety and antitumor activity of oleclumab in adult Japanese patients with advanced solid malignancies. The results showed that oleclumab was well tolerated and no unexpected safety concerns were raised.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Jill J. J. Geenen, Gwen M. H. E. Dackus, Philip C. Schouten, Dick Pluim, Serena Marchetti, Gabe S. Sonke, Katarzyna Jozwiak, Alwin D. R. Huitema, Jos H. Beijnen, Jan H. M. Schellens, Sabine C. Linn
Summary: A dose finding study of olaparib tablets bidaily (BID) continuously with carboplatin in advanced cancer patients showed that the combination treatment was feasible and tolerable, with dose-level 3 (olaparib 75 mg BID and carboplatin AUC 4 mg*min/mL) defined as the maximum tolerable dose (MTD). The study also indicated a comparable systemic exposure of the olaparib tablet formulation to the previous capsule formulation. Additionally, the treatment schedule resulted in a partial response in 56% of the patients with common adverse events including nausea and fatigue.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Yu Sunakawa, Keishiro Takahashi, Osamu Kawaguchi, Nobuyuki Yamamoto
Summary: This study aimed to determine the recommended dose of aflibercept combined with docetaxel for Japanese patients with advanced solid malignancies. The study found that the combination treatment caused febrile neutropenia and did not maintain the desired level of free aflibercept in excess of the VEGF-bound form.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Summary: This study evaluated the recommended dose, maximum tolerated dose, and pharmacokinetic profile of Trametinib in patients with advanced solid tumors and various degrees of hepatic dysfunction. The recommended dose for patients with mild hepatic dysfunction was 2 mg daily. However, due to difficulty in patient accrual, the recommended dose and maximum tolerated dose could not be determined for patients with moderate and severe hepatic dysfunction. Treatment-related adverse events were consistent with previous studies.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K. Williamson, Joaquina Baranda, Hirva Mamdani, Ya-Li Lee, Li Li, Xingli Wang, Xunwei Dong
Summary: FN-1501, a novel intravenous FLT3 inhibitor, has shown potential efficacy and safety for patients with advanced solid tumors. The maximum tolerated dose (MTD) of FN-1501 was determined to be 170 mg, demonstrating reasonable safety, tolerability, and preliminary activity against solid tumors.
